Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW Panel Approves List of “Stable Supply Medicines”; Pricing to Become Topic of Discussions
A panel of the Ministry of Health, Labor and Welfare (MHLW) on March 26 approved a list of 506 APIs deemed to be essential in clinical practices, called “stable supply medicines.” The panel on stable drug supplies was launched in March…
To read the full story
Related Article
- Japan Finalizes Designation of 762 “Supply-Ensured Medicines”
October 28, 2025
- Japan to Expand List of “Stable Supply Medicines” to 759 APIs, Adding Vaccines and Blood Products
August 28, 2025
- MHLW Working Group Sets Policy for Revising List of “Stable Supply Medicines”
August 18, 2025
- MHLW Working Group Begins Discussions to Update List of “Stable Supply Medicines”
May 22, 2025
- MHLW to Update List of “Stable Supply Medicines” Eyeing Expansion
October 25, 2024
- Legal Initiatives Necessary to Ensure Stable Drug Supplies: MHLW Official
March 28, 2022
- MHLW Unveils List of “Stable Supply Medicines”
March 2, 2021
- Working Group Agrees to Designate 10-20 “Stable Supply Medicines” as Top Priority Drugs
November 4, 2020
- 1st Working Group Meeting for Prioritization of “Stable Supply Medicines” Set for Early November
October 26, 2020
REGULATORY
- Nakai Tapped as MHLW’s Top Pharmacy Officer; Ohara to Steer Drug Pricing Reform
August 7, 2026
- Sarclisa SC, Joenja, Kineret, and 7 More Drugs Bound for NHI Listing
August 6, 2026
- Tepezza Price Cut Set at 5.5% under Japan’s CEA Scheme
August 6, 2026
- Dupixent Faces Fourth Re-Pricing under Japan’s SPA-SSS
August 6, 2026
- Chuikyo Clears NHI Listing for Oncolys’ Telomelysin
August 6, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…